Small-scale biotech Target opportunity in non-opioid pain therapeutics for both human and animal health, suggesting potential partnerships or licensing discussions around EC5026 or related analgesic programs.

FDA Fast Track Leverage the existing FDA Fast Track designation to accelerate clinical collaboration, advisory input, and potential early-stage partnerships or funding discussions with larger pharma seeking accelerated pain market entries.

Strategic funding Capitalize on past and ongoing external funding (SBIR grants and Open Philanthropy investment) as a validation signal to attract co-development partners, contract research organizations, or joint ventures to advance clinical trials.

UC Davis connection Highlight the university-origin research from UC Davis to pursue academic collaborations, licensing talks, or sponsored research agreements that can de-risk development and expand investor interest.

SBIR/NIH path Explore opportunities to secure additional NIH or SBIR funding for current programs, enabling milestones-based partnerships with contract manufacturers and potential customers in human and veterinary pain management markets.